Writing
Articles and insights on Biotechnology, Drug Discovery, Pharmaceutical AI.
Truth Rather Than Belief
In Truth Rather Than Belief , David Berry explores how scientific consensus can limit innovation and why challenging established assumptions, following the data, and embracing unconventional ideas are essential to breakthrough discoveries.
Building The AI Powered Hospital
Michael Hasselberg of Nebraska Medicine joins David Berry on Averin Insights to discuss in-house AI, technology partnerships, and the hospital of the…
Accelerating the Speed of Discovery
What does it take to accelerate drug discovery without losing the scientific judgment that makes better medicines possible? I sit down with Andy Plump,…
The Case for Drug Abundance
What if the cost of developing a medicine no longer determined which diseases get treated? The Case for Drug Abundance explores how advances in AI, human…
Betting on Breakthrough Biology
How do you spot the next big idea in biotech before everyone else does? I sit down with Christian Schubert, Vice President and Global Head of AbbVie…
Before Disease Decides
What if diagnostics could tell us not just what disease a patient has, but what is beginning to happen next? I sit down with QIAGEN CEO Thierry Bernard…
Welcoming Dr. Mikael Dolsten to the Averin Advisory Board
We are excited to announce that Dr. Mikael Dolsten has joined Averin Capital as an advisor. A physician-scientist and biotechnology leader with more than…
The Surgeon Is Still the System
The next era of surgery will not be defined by robots alone, but by integrated systems of AI, visualization, and precision tools that expand what surgeons…
Diagnostics Isn’t Broken. Our Model for Evaluating It Is
Investor sentiment has turned against diagnostics, but for the wrong reasons. Recent failures have hardened a lazy narrative that the category is…
Regulation, AI, and Geopolitics: Insights from Our Latest Fireside Chat
In a candid conversation with Peter Hutt, David Shulkin, and Daniel Troy, we cut through headline noise to find a clear pattern - despite few formal…
The FDA’s Shifting Regulatory Landscape
The FDA has shifted from a distant gatekeeper to an active force shaping how health-tech companies build, sell, and exit. Regulatory cycles are…
AI’s Leap in Healthcare and Biotech: Insights from Our Latest Fireside Chat
Averin’s David Berry hosts a conversation with leaders from XYME, AWS, and Bioptic to explore how AI is transforming drug discovery, data infrastructure,…